A new study from the Hudson Lab at the University of Glasgow shows that the FFA receptor antagonist AH7614 is actually an inverse agonist - suppressing fat cell formation, boosting lipolysis and reducing glucose uptake. Explore how targeting FFA4 could help fight metabolic disorders.

Catch up with the latest research conducted in the Hudson lab in Ep. 161 of the Dr. GPCR Podcast.

Subscribe to the Dr. GPCR Newsletter 📰 and get the latest GPCR News delivered to your inbox

➡️https://www.ecosystem.drgpcr.com/gpcrs-in-cardiology-endocrinology-and-taste/inverse-agonism-of-the-ffa4-free-fatty-acid-receptor-controls-both-adipogenesis-and-mature-adipocyte-function

#GPCR #drGPCR #FFA4 #metabolism #adipocytes”